Document Detail


Cancer stem cells in head and neck squamous cell cancer.
MedLine Citation:
PMID:  18539966     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Appropriate treatment of head and neck squamous cell cancer (HNSCC) remains one of the most difficult challenges in head and neck oncology. Overall survival of patients with HNSCC remains at approximately 50% at 5 years. Surgical therapy can be mutilating and often has significant effects on swallowing, speech, and physical appearance. The addition of chemotherapy to radiation treatment has shown efficacy in organ preservation in some sites in the head and neck, but has resulted in limited improvement in survival rates. HNSCC resistance to chemotherapy has limited the usefulness of chemotherapy in the treatment of this disease. We have recently demonstrated that human head and neck squamous cell cancers contain a tumorigenic, so-called cancer stem cell, subpopulation of cells that can self-renew and produce differentiated cells that form the bulk of the tumor. These tumorigenic HNSCC cells have a distinct phenotype and can be identified by a surface marker. Current treatment for HNSCC regimens may selectively kill the differentiated cancer cells, producing tumor regression while sparing the cancer stem cells, leading to tumor regrowth and relapse. It is important for us to understand why HNSCC does not respond to chemotherapy and to identify new targeted treatments that can overcome resistance and improve patient outcomes. Further study of HNSCC stem cells will increase our knowledge of this devastating disease and allow us to develop novel treatments.
Authors:
Mark E P Prince; Laurie E Ailles
Related Documents :
7940126 - The importance of the timing of a gap in radiotherapy of squamous cell carcinomas of th...
23120466 - Clinicopathological and radiological evaluation of cervical lymph node metastasis in he...
25163656 - Adenocarcinomas of the upper third of the rectum and the rectosigmoid junction seem to ...
11870186 - Maximizing local control and organ preservation in stage iv squamous cell head and neck...
19101096 - Preoperative [18f]fluorodeoxyglucose positron emission tomography standardized uptake v...
16782926 - Phase iii randomized trial of very accelerated radiation therapy compared with conventi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  26     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-09     Completed Date:  2008-06-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2871-5     Citation Subset:  IM    
Affiliation:
University of Michigan, Otolaryngology-HNS, 1904 Taubman Center, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA. mepp@umich.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology,  therapeutic use
Drug Resistance, Neoplasm
Head and Neck Neoplasms / drug therapy,  metabolism,  pathology*
Humans
Neoplasms, Squamous Cell / drug therapy,  metabolism,  pathology*
Neoplastic Stem Cells / drug effects,  pathology*
Phenotype
Tumor Markers, Biological / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prostate cancer stem cells: a new target for therapy.
Next Document:  Gastric cancer stem cells.